Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice.

Echarri A, Ollero V, Barreiro-de Acosta M, Fernández-Villaverde A, Hernández V, Lorenzo A, et al.

Eur J Gastroenterol Hepatol. 2015 Apr;27(4):430-5. doi: 10.1097/MEG.0000000000000296

Bionical